Screening breast, ovarian cancer gene mutations other than BRCA1/2 impact management
the ONA take:
Multigene testing for hereditary breast and/or ovarian cancer that tests for more gene mutations than BRCA1/2 is more likely to inform clinical decision-making than testing for BRCA1/2 alone, according to a new study published online ahead of print in JAMA Oncology.
"The traditional approach has been to test most women with suspected hereditary risk for breast and/or ovarian cancer for BRCA1/2 alone," senior author Leif Ellisen, MD, PhD, program director for Breast Medical Oncology at the MGH Cancer Center said.
Of 1,046 study participants, 40 BRCA1/2-negative patients harbored deleterious mutations. The most common mutations were in CHECK2, ATM, PALB2, and Lynch syndrome genes. Researchers found that for the majority those and an additional 23 mutation-positive patients their clinics, additional disease-specific screening and/or prevention measures other than those based on personal and family history alone would be considered.
"Our study shows that, even under current practice guidelines, finding mutations in these other genes is likely to change the clinical management recommendations both for patients and for family members who also carry the associated mutations," explains Dr. Ellisen.
Multigene testing for hereditary breast and/or ovarian cancer that tests is more likely to inform clinical decision-making than testing for BRCA1/2 alone.
- Health Care Expansion Tied to Increased Rates of Surgical Treatment of Thyroid Cancer
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Hormone Refractory Prostate Cancer Responds to Abiraterone Acetate in Some Cases
- Beans, Whole Grains in Diet Beneficial for Colorectal Cancer Survivors
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Rubraca Granted Accelerated FDA Approval for Advanced BRCA-positive Ovarian Cancer
- New Criteria for Appropriate Use of Bone Scintigraphy to Diagnose and Manage Prostate and Breast Cancer
- Primary Care Physicians Surveyed on Breast Cancer Screening Practices
- Low Acculturated Latina Women Reported Breast Cancer Treatment Experience Differently Than Other Groups
- Cost and Complication Rates Differ Among Early Breast Cancer Treatment Options
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|